HEMATOLOGY

NKX101 and NKX019 showed early signs of safety and efficacy in treatment of heavily pretreated patients with acute myeloid leukemia and non-Hodgkin lymphoma.

Total body irradiation (TBI) regimen and myeloablative transplantation followed by a graft-versus-host disease (GVHD) prophylaxis regimen resulted in a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies

Based on an interim analysis of a randomized phase 2 trial, use of topical ruxolitinib showed reduced body surface area of chronic graft-versus-host disease.

In an interview with Targeted Oncology, Basem Goueli, MD, PhD, MBA, discussed the recent crackdown on PI3K inhibitors and how this drug class may fit into future treatment for hematologic malignancies as well as solid tumors.

The majority of patients treated in a phase 1 trial of belimumab used as chronic graft-vs-host-disease prophylaxis showed no evidence of the disease after 20 months of follow-up.

In the prospective, double-blind, phase 2 randomized controlled trial, in which investigators evaluated the efficacy and safety of topical ruxolitinib, a novel gene signature was identified.

In a 16 to 0 vote, the FDA’s Oncologic Drugs Advisory Committee has voted yes to future approvals of PI3K inhibitors being supported by randomized data given observed toxicities in the drug class, research showing a detriment in OS, a narrow range between effective, and toxic doses.

During a Targeted Oncology case-based roundtable event, Matthew A. Davids, MD, MMSc, discussed key considerations for prophylaxis and the use of rasburicase in managing tumor lysis syndrome.

Magrolimab clinical trials including patients with myelodysplastic syndrome and acute myeloid leukemia may continue now that the FDA has lifted a partial clinical hold.

During a presentation, Paul G. Richardson, MD, talked about the shift from triplet combination therapies toward quadruplet combinations for the treatment of multiple myeloma.

Guenther Koehne, MD, PhD, discusses the exciting presentations going on at the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

In pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia who had a non-response to blinatumomab and a high-disease burden, worse outcomes were observed , according to retrospective research.

Closing out their discussion on graft-versus-host disease, participants reflect on patient prognoses and the future directions of care.

A brief discussion on the risk of treatment-induced damage when managing patients with chronic graft-versus-host disease.

Having reviewed approved treatment options for steroid-refractory, chronic GVHD, experts discuss how they would address this patient scenario.

Considerations for belumosudil and axatilimab as treatment options for steroid-refractory chronic graft-versus-host disease.

A review of treatment options approved for steroid-refractory chronic graft-versus-host disease starting with ibrutinib and ruxolitinib.

Shared insight on how to distinguish chronic GVHD from acute GVHD, as well as utilize appropriate methods to risk stratify disease.

Shifting their focus to chronic graft-versus-host disease, experts review a patient scenario and discuss the challenges in early intervention.

AZALENA trial shows encouraging response rates, duration of response and survival including patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia with MDS-related changes.

Experts review the prognosis of a patient with acute graft-versus-host disease and identify ways to optimize their treatment strategies.

A panel of experts discuss systemic therapy to manage a patient with acute graft-versus-host disease.

Centering discussion on a patient scenario of acute graft-versus-host disease, participants discuss nuance in disease symptomology and patient education.

Expert perspectives on the nature and occurrence of graft-versus-host disease alongside available prophylactic regimens.